Cariprazine Augmentation in Inadequate Clozapine Response: A Case Series
Published: June 1, 2024 | DOI: https://doi.org/10.7860/JCDR/2024/69088.19525
SS Asha Charitha, Soumya S Sobhan, Jibi Achamma Jacob Rajesh Gopalakrishnan, Anju Kuruvilla
1. Assistant Professor, Department of Psychiatry, Christian Medical College, Vellore, Tamil Nadu, India. ORCID-0000-0002-8114-7471
2. Assistant Professor, Department of Psychiatry, Christian Medical College, Vellore, Tamil Nadu, India. ORCID-0009-0004-3212-0231
3. Associate Professor, Department of Psychiatry, Christian Medical College, Vellore, Tamil Nadu, India. ORCID-0000-0003-0078-3730
4. Professor, Department of Psychiatry, Christian Medical College, Vellore, Tamil Nadu, India. ORCID-0000-0002-9137-6219
5. Professor, Department of Psychiatry, Christian Medical College, Vellore, Tamil Nadu, India. ORCID-0000-0003-1708-1620
Correspondence
Dr. Jibi Achamma Jacob,
Associate Professor, Department of Psychiatry, Christian Medical College, Vellore-632002, Tamil Nadu, India.
E-mail: jibiachamma@gmail.com
Managing patients with treatment-resistant schizophrenia who do not respond adequately to Clozapine poses a challenge. Cariprazine, with its unique mechanism of action, may be an option for such patients. The additional benefits of using Cariprazine as an augmentation strategy include once-daily dosing, ease of titration, and a favourable side-effect profile. The report outlines the authors’ experience of six patients with treatment-resistant schizophrenia who did not respond to Clozapine. The addition of Cariprazine was tolerated by all the patients. The majority showed improvement with symptom reduction, and in some cases, the dose of Clozapine could be reduced, thereby decreasing the side-effects of Clozapine.
[
FULL TEXT ] | [ PDF]